ArticleCommunications biology2021
A four-gene signature predicts survival and anti-CTLA4 immunotherapeutic responses based on immune classification of melanoma.
Article in Communications biology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- The entanglement of extracellular matrix molecules and immune checkpoint inhibitors in cancer: a systematic review of the literature.Frontiers in immunology · 2023Pooled it
- Robust prioritization of genomic features with stability selection.Bioinformatics (Oxford, England) · 2026Article
- Exploring the immune landscape of melanoma of the lower female genital tract.Virchows Archiv : an international journal of pathology · 2026Article
- Bioinformatics analysis reveals novel tumor antigens and immune subtypes of skin cutaneous melanoma contributing to mRNA vaccine development.Frontiers in immunology · 2025Article
- A375 melanoma-derived lactate controls A375 melanoma phenotypes by inducing macrophage M2 polarizationPeerJ · 2025Article
- Article
- A seven-immune-genes risk model predicts the survival and suitable treatments for patients with skin cutaneous melanoma.Heliyon · 2023Article
- MOBILE pipeline enables identification of context-specific networks and regulatory mechanisms.Nature communications · 2023Article
- Article
- Comprehensive Analysis of Necroptosis Landscape in Skin Cutaneous Melanoma for Appealing its Implications in Prognosis Estimation and Microenvironment Status.Journal of personalized medicine · 2023Article
- Effective oxygen metabolism-based prognostic signature for colorectal cancer.Frontiers in oncology · 2023Article
- Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy.Frontiers in immunology · 2023Article
- Construction and Identification of an NLR-Associated Prognostic Signature Revealing the Heterogeneous Immune Response in Skin Cutaneous Melanoma.Clinical, cosmetic and investigational dermatology · 2023Article
- Identification of Pyroptosis-Relevant Signature in Tumor Immune Microenvironment and Prognosis in Skin Cutaneous Melanoma Using Network Analysis.Stem cells international · 2023Article
- MEMMAL: A tool for expanding large-scale mechanistic models with machine learned associations and big datasets.Frontiers in systems biology · 2023Article
- Identification of a predictive gene signature related to pyroptosis for the prognosis of cutaneous melanoma.Medicine · 2022Article
- Crosstalk of four kinds of cell deaths defines subtypes of cutaneous melanoma for precise immunotherapy and chemotherapy.Frontiers in immunology · 2022Article
- Prognostic signature and immune efficacy of mJournal of cellular and molecular medicine · 2021Article
- Comprehensive Analysis of a Nine-Gene Signature Related to Tumor Microenvironment in Lung Adenocarcinoma.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Cutaneous melanoma is the most malignant skin cancer. Biomarkers for stratifying patients at initial diagnosis and informing clinical decisions are highly sought after. Here we classified melanoma patients into three immune subtypes by single-sample gene-set enrichment analysis. We further identified a four-gene tumor immune-relevant (TIR) signature that was significantly associated with the overall survival of melanoma patients in The Cancer Genome Atlas cohort and in an independent validation cohort. Moreover, when applied to melanoma patients treated with the CTLA4 antibody, ipilimumab, the TIR signature could predict the response to ipilimumab and the survival. Notably, the predictive power of the TIR signature was higher than that of other biomarkers. The genes in this signature, SEL1L3, HAPLN3, BST2, and IFITM1, may be functionally involved in melanoma progression and immune response. These findings suggest that this four-gene signature has potential use in prognosis, risk assessment, and prediction of anti-CTLA4 response in melanoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.